UltraSPECT Xpress.cardiac gains FDA 510K approval
UltraSPECT has recently been granted U.S. Federal Food and Drug Administration (FDA) 510K clearance for the marketing of its Xpress.cardiac product, which cuts myocardial perfusion SPECT acquisition time by 50 percent with no degradation in image quality, UltraSPECT said.
Offering an improvement in SPECT scanning efficiency, Xpress.cardiac utilizes UltraSPECT's patented Wide Beam Reconstruction (WBR) technology to significantly boost throughput and reduce patient motion artifacts.
Current American College of Cardiology (ACC) guidelines for myocardial perfusion gated stress SPECT scan times range from 12 to 25 minutes. However, Xpress.cardiac can complete a diagnostic quality gated stress image scan in as few as five minutes.
Xpress.cardiac will debut at the 2005 Annual Meeting of the Society of Nuclear Medicine in Toronto, Canada. WBR technology is also incorporated in UltraSPECT's Xact.bone and Xpress.bone imaging products currently in use in more than 20 sites in the U.S. and Israel.
Offering an improvement in SPECT scanning efficiency, Xpress.cardiac utilizes UltraSPECT's patented Wide Beam Reconstruction (WBR) technology to significantly boost throughput and reduce patient motion artifacts.
Current American College of Cardiology (ACC) guidelines for myocardial perfusion gated stress SPECT scan times range from 12 to 25 minutes. However, Xpress.cardiac can complete a diagnostic quality gated stress image scan in as few as five minutes.
Xpress.cardiac will debut at the 2005 Annual Meeting of the Society of Nuclear Medicine in Toronto, Canada. WBR technology is also incorporated in UltraSPECT's Xact.bone and Xpress.bone imaging products currently in use in more than 20 sites in the U.S. and Israel.